Compare UMBF & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UMBF | GH |
|---|---|---|
| Founded | 1913 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 14.1B |
| IPO Year | N/A | 2018 |
| Metric | UMBF | GH |
|---|---|---|
| Price | $119.21 | $102.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | ★ $136.27 | $96.48 |
| AVG Volume (30 Days) | 525.3K | ★ 2.0M |
| Earning Date | 01-27-2026 | 10-29-2025 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 10.98 | N/A |
| EPS | ★ 8.89 | N/A |
| Revenue | ★ $2,217,071,000.00 | $902,569,000.00 |
| Revenue This Year | $69.52 | $35.00 |
| Revenue Next Year | $7.83 | $26.80 |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | ★ 45.52 | 30.38 |
| 52 Week Low | $82.00 | $29.91 |
| 52 Week High | $126.14 | $112.43 |
| Indicator | UMBF | GH |
|---|---|---|
| Relative Strength Index (RSI) | 62.94 | 56.39 |
| Support Level | $118.17 | $96.28 |
| Resistance Level | $120.26 | $105.01 |
| Average True Range (ATR) | 2.31 | 4.05 |
| MACD | 0.27 | -1.12 |
| Stochastic Oscillator | 80.80 | 48.98 |
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.